1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BIONTECH : Goldman Sachs reaffirms its Neutral rating

01/12/2022 | 09:17am EDT

Goldman Sachs analyst Chris Shibutani maintains his Neutral opinion on the stock. The target price has been raised from USD 289 to USD 299.


© MarketScreener with dpa-AFX Analyser 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -4.07% 156.61 Delayed Quote.-36.69%
ON SEMICONDUCTOR CORPORATION -2.43% 54.535 Delayed Quote.-17.71%
All news about BIONTECH SE
11:13aGoldman Sachs Adjusts BioNTech's Price Target to $206 from $255, Keeps Neutral Rating
MT
05/23Wall Street rebounds with assist from banks, big tech
RE
05/23GLOBAL MARKETS LIVE : Tesla, Kohl's, Apple, JPMorgan, Bank of America...
05/23WALL STREET STOCK EXCHANGE : Biden comments reassure investors
05/23Pfizer says 3 shots of COVID-19 vaccine for children under 5 about 80% effective
AQ
05/23BIONTECH : Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Effi..
PU
05/23What you need to know about the coronavirus right now
RE
05/23Pfizer, BioNTech Say Third Dose of COVID-19 Vaccine About 80% Effective in Children Age..
MT
05/23Pfizer, BioNTech Publish Data Supporting COVID-19 Vaccine Efficacy In Children Aged Six..
MT
05/23Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and..
GL
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2022 16 941 M 18 103 M 18 103 M
Net income 2022 9 121 M 9 747 M 9 747 M
Net cash 2022 15 700 M 16 777 M 16 777 M
P/E ratio 2022 4,38x
Yield 2022 -
Capitalization 37 119 M 39 666 M 39 666 M
EV / Sales 2022 1,26x
EV / Sales 2023 1,11x
Nbr of Employees 3 082
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 152,74 €
Average target price 224,49 €
Spread / Average Target 47,0%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-36.69%39 666
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
GENMAB A/S-18.02%20 276